Boka provided a story in addition to toothpaste. One where smiles could be brighter without sacrificing quality, and enamel could be strengthened without fluoride.
It seemed like a welcome promise to an increasing number of consumers, particularly those who are looking at labels for alternatives. Their goods were based on nano-hydroxyapatite, a synthetic mineral that NASA first created to aid space travelers in preventing bone loss and dental decay.
| Detail | Information |
|---|---|
| Company | Essor Group, Inc. |
| Brand | Boka Oral Care |
| Ingredient Focus | Nano-Hydroxyapatite (n-HA) |
| Disputed Marketing Claims | Remineralization, Whitening, and Prebiotic Mouthwash Benefits |
| Regulatory Findings | NAD and NARB recommended discontinuation of unsupported product claims |
| Appeal Status | Essor appealed but ultimately complied with NARB recommendations |
| Challenger | Procter & Gamble (Crest brand) |
| Oversight Body | BBB National Programs – National Advertising Division (NAD) |
Boka promoted this same mineral as a safer, scientifically validated substitute for fluoride, which was long the industry standard. However, the business went beyond merely outlining its formula. They used bold language in their marketing materials, such as “remineralizes enamel,” “fortifies teeth,” and “supports a healthy microbiome.”
Procter & Gamble, the company that makes Crest, eventually took notice of that assertive and appealing tone. By May 2025, the National Advertising Division, a regulatory agency, was preparing for a high-stakes advertising review—but not in a courtroom.
Under the auspices of BBB National Programs, the NAD reviewed the supporting documentation that Essor Group provided. They discovered something interesting, but not in the way Boka had hoped.
Essor mainly relied on research that used nano-hydroxyapatite as a separate component. Nevertheless, the complete Boka toothpaste product was not tested in any of those studies. That particular detail turned out to be crucial.
This was very important from a regulatory standpoint. Product-specific testing is required to support any claims regarding the advantages of a product, including whitening or enamel fortification. Although intriguing, ingredient-level evidence was insufficient.
I was struck by how subtly firm the language was when I read the NAD report’s phrase, “no reasonable basis for claims that its oral care products provide teeth whitening.” Not a direct charge, but a categorical denial of assumption-as-proof.
Essor maintained that its composition, which included abrasives like sodium bicarbonate and silica, along with brushing action, could logically account for whitening and stain removal. However, plausibility is not proof. Additionally, regulators are now leaning more toward certainty.
The results were upheld by July 2025 following an appeal to the National Advertising Review Board. Essor was advised to stop making several claims, such as that its toothpaste could whiten teeth, remineralize enamel, or use prebiotics to improve breath.
Particularly, the mouthwash claims fell short of expectations. Despite mentioning research on a prebiotic called preBIULIN, none of the studies showed a link between the product’s formulation and better breath.
When faced with this result, Essor gave up. The business agreed to comply even though it expressed “strong disagreement” with the findings. Simultaneously, it reiterated its dedication to ongoing scientific investigation, portraying itself as resolute rather than defeated.
False advertising in the conventional sense was not the issue here. It was more subtle—a challenge to the increasingly widespread practice of drawing conclusions from larger scientific studies without conducting tests on the particular product being marketed.
Customers had real-world concerns about the situation. Does it matter that some of the toothpaste’s claims were found to be false if it’s still safe? Whether trust is based on safety alone or also on accountability and transparency depends on how we define it.
Additionally, it was a silent wake-up call for a booming industry sector. Once a niche market, fluoride-free products are now widely available on store shelves and in influencer reels. Cautious optimism and a predilection for supposedly “clean” alternatives have contributed to that popularity.
However, scrutiny has come. And it’s not going anywhere.
The standard for what constitutes “scientific backing” was essentially raised by the Boka case. Saying an ingredient can do something is no longer sufficient. Nowadays, brands must demonstrate that their real product performs as promised—reliably, demonstrably, and under real-world circumstances.
For certain patients, particularly those who are sensitive to fluoride, some dentists still advocate hydroxyapatite. Others are still adamantly in favor of fluoride, citing decades of empirical evidence and its demonstrated effectiveness. It is evident that customers are torn between those viewpoints.
It’s interesting to note that Boka wasn’t the only target of this lawsuit. Lead, mercury, and even arsenic were among the trace heavy metals in n-HA formulations that some independent testers found concerning. Those reports, while not specific to Boka, added a level of concern.
The regulatory rulings concentrated on marketing accuracy rather than toxicity. However, they also indicated a more general change: regulatory agencies are becoming more attentive, especially when promises pertaining to health are being made.
From the standpoint of the market, the case generated both opportunity and pressure. Clinical testing will now be expected of brands. In crowded consumer categories, those who do might stand out not only for the quality of their products but also for their credibility.
And for purchasers? The necessity of healthy skepticism is emphasized throughout the entire episode. What’s going on behind the scenes isn’t always reflected in a beautiful website or eye-catching packaging.
However, the purpose of this story is not to raise doubts. It’s a flash of insight. An indication that creativity and responsibility can and ought to coexist.
From this perspective, the Boka decision seems more like a recalibration than a setback. One that might eventually result in better testing, more robust products, and ambitious, evidence-based marketing.
With a revised message and, hopefully, a renewed emphasis on research, Boka is still on the shelves for the time being. Instead of following trends, transparency may attract new users and retain existing ones.
In the end, the toothpaste section has turned into a testing ground for trust as much as products. And maybe that’s exactly what this area needed—a lot more proof and a bit less polish.
